ROXIFIBAN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H29N5O6
Molecular Weight	447.4849
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCOC(=O)N[C@@H](CNC(=O)C[C@H]1CC(=NO1)C2=CC=C(C=C2)C(N)=N)C(=O)OC

InChI

InChIKey=IRAXRQFCCSHQDX-WBVHZDCISA-N

InChI=1S/C21H29N5O6/c1-3-4-9-31-21(29)25-17(20(28)30-2)12-24-18(27)11-15-10-16(26-32-15)13-5-7-14(8-6-13)19(22)23/h5-8,15,17H,3-4,9-12H2,1-2H3,(H3,22,23)(H,24,27)(H,25,29)/t15-,17+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C21H29N5O6
Molecular Weight	447.4849
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8970768 | https://www.ncbi.nlm.nih.gov/pubmed/14727937 | https://www.ncbi.nlm.nih.gov/pubmed/11904529 | https://adisinsight.springer.com/drugs/800006832

Roxifiban (also known as DMP754), a potent antiplatelet agent in inhibiting platelet aggregation, and has a high specificity and affinity for human platelet glycoprotein IIb/IIIa complex (GPIIb/IIIa) receptors. Roxifiban participated in clinical trials phase III for the treatment of peripheral arterial disorders. This drug was also well tolerated in patients with chronic stable angina pectoris and was studied in the treatment of heparin-induced thrombocytopenia, and thrombosis. However, the development of this drug appears to have been discontinued.

Approval Year

PubMed

Title	Date	PubMed
Oral antiplatelet efficacy of the platelet GPIIb/IIIa antagonist, DMP754 in non-human primates.	1998 Mar 1	9645915
Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis.	2002 Apr	11904529
The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease.	2003	14727937
[Long-lasting thrombocytopenia induced by glycoprotein IIb/IIIa inhibitor].	2017 Nov	28690092

Patents

Sample Use Guides

In Vivo Use Guide

Ninety-eight patients were randomized to receive either a placebo or 1 of 8 oral dosages of roxifiban. Twenty-two patients were enrolled in multiple-dose regimens, bringing the total study population to 120. The oral dosages were 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, or 2.5 mg/day for up to 30 days.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:36:47 GMT 2023` Edited by `admin` on `Fri Dec 15 18:36:47 GMT 2023`
Record UNII	Q476FMZ72G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ROXIFIBAN

Official Name

English

L-ALANINE, 3-(((3-(4-(AMINOIMINOMETHYL)PHENYL)-4,5-DIHYDRO-5-ISOXAZOLYL)ACETYL)AMINO)-N-(BUTOXYCARBONYL)-, METHYL ESTER, (R)-

Common Name

English

roxifiban [INN]

Common Name

English

Roxifiban [WHO-DD]

Common Name

English

(2S)-3-(2-((5R)-3-(P-AMIDINOPHENYL)-2-ISOXAZOLIN-5-YL)ACETAMIDO)-2-(CARBOXYAMINO)PROPIONIC ACID, 2-BUTYL METHYL ESTER

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1327